Read up on our latest news

The founders of Mirvie are tapping into their expertise in RNA science and oncology to address gaps in maternal health with a platform that can predict pregnancy complications, such as preeclampsia, before they happen.

New tools like Encompass™ by Mirvie let you predict your personal risk for preeclampsia months before symptoms appear. It’s a simple at-home blood test you take between 18–22 weeks, and it uses groundbreaking RNA science to analyze thousands of signals from you, your baby, and the placenta.

When we learned about Encompass™, a simple at-home blood test that can predict your risk of developing preeclampsia months before symptoms appear, our first thought was: why isn’t this already the standard of care?

Until recently, preeclampsia could only be diagnosed after symptoms appeared. But now, researchers are exploring ways to predict risk earlier. A newly launched at-home blood test, Encompass™, is one of the latest tools being studied to give families and providers a potential early warning—months before symptoms might develop.

The first and only at-home blood test that predicts a pregnant person’s risk of developing preeclampsia has launched. Known as Encompass, the test from Mirvie can predict the condition months before symptoms appear, giving pregnant people time to take preventative steps.

Mirvie Inc. continues the development of precision medicine for pregnancy-related conditions with its Encompass blood test to predict preeclampsia risk and individualized support to head off the life-threatening complication that affects one in 12 pregnancies.

Often detected only after symptoms appear, preeclampsia is the second leading cause of maternal death. See how the new Encompass test could help identify risk earlier and save lives.

Aimee Corso, senior vice president of growth at Mirvie, discusses the women's health company's direct-to-consumer test to help pregnant women predict preeclampsia before its onset through RNA analysis during 18 to 22 weeks of gestation.

Encompass™ combines a novel blood test to predict personalized preeclampsia risk with a preventive action plan and a responsive virtual assistant

Mirvie has launched Encompass, a solution that combines a blood test to predict personalized preeclampsia risk with preventive planning tools, the company announced today.